STOCK TITAN

Dr. Peter Staats to Host Analyst Day on the Science Behind gammaCore™ Non-Invasive Vagus Nerve Stimulation (nVNS) on Tuesday, November 21, 2023

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
electroCore, Inc. (Nasdaq: ECOR) announces its Chief Medical Officer, Dr. Peter Staats, will host an analyst day on November 21, 2023, to discuss the potential of Vagus Nerve Stimulation with gammaCore™. The webinar will cover the nVNS mechanism of action and potential pipeline of indications using the company’s proprietary nVNS technology platform embodied in its gammaCore product.
Positive
  • None.
Negative
  • None.

ROCKAWAY, N.J., Nov. 15, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that the Company’s Chief Medical Officer, Dr. Peter Staats will host an analyst day entitled “Accessing the Power of Vagus Nerve Stimulation with gammaCore™” on November 21, 2023 at 1:30pm EST. The webinar will cover the nVNS mechanism of action and potential pipeline of indications using the company’s proprietary nVNS technology platform that is embodied in its gammaCore product.

Analyst Day: “Accessing the Power of Vagus Nerve Stimulation with gammaCore™
Date: Tuesday, November 21, 2023
Time: 1:30pm – 2:30pm EST
Registration: https://electrocore.zoom.us/webinar/register/WN_wcHtB4caT--D58SYPiyryw

Participants interested in listening to the webinar can register by clicking here. Following the live presentation, a playback of the webinar will be available on the “Investors” section of the company’s website at: www.electrocore.com.

About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving health through its nVNS technology platform. Our focus is the commercialization of medical devices for the management and treatment of certain medical conditions and consumer product offerings utilizing nVNS to promote general wellbeing and human performance in the United States and select overseas markets.

For more information, visit www.electrocore.com.

Forward-Looking Statements
This press release and other written and oral statements made by representatives of electroCore may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about expectations for revenue for 2023 and beyond, electroCore’s business prospects and clinical and product development plans; its pipeline or potential markets for its technologies; the timing, outcome and impact of regulatory, clinical and commercial developments; business prospects around its Truvaga wellness and TAC-STIM human performance offerings and other new products and markets, and other statements that are not historical in nature, particularly those that utilize terminology such as "anticipates," "will," "expects," "believes," "intends," and other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue electroCore’s business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize gammaCore™, TAC-STIM™, and Truvaga™, the potential impact and effects of COVID-19 on the business of electroCore, electroCore’s results of operations and financial performance, inflation and currency fluctuations, and any expectations electroCore may have with respect thereto, competition in the industry in which electroCore operates and overall economic and market conditions. Any forward-looking statements are made as of the date of this press release, and electroCore assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents electroCore files with the SEC available at www.sec.gov.

Contact:
ECOR Investor Relations
(973) 302-9253
investors@electrocore.com 


FAQ

What is the topic of electroCore's analyst day?

The topic is “Accessing the Power of Vagus Nerve Stimulation with gammaCore™.”

When will the analyst day take place?

The analyst day will be on November 21, 2023, from 1:30pm to 2:30pm EST.

How can participants register for the webinar?

Participants can register by clicking on the following link: https://electrocore.zoom.us/webinar/register/WN_wcHtB4caT--D58SYPiyryw

Where can participants find the playback of the webinar after the live presentation?

The playback will be available on the “Investors” section of the company’s website at www.electrocore.com.

electroCore, Inc.

NASDAQ:ECOR

ECOR Rankings

ECOR Latest News

ECOR Stock Data

109.85M
4.91M
25.02%
16.11%
0.67%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States of America
ROCKAWAY